X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding aims to support Radiant to develop the next generation of HIV biologics based on Radiant’s Multabody platform, which can destroy latent stores of the HIV virus, along with its ability to eliminate circulating viral particles.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 20, 2023
Details:
The financing will advance and validate Radiant's Multabody platform among several oncology programs. Radiant’s Multabody platform exploits avidity - stronger binding power - coupled with multi-specificity to deliver highly efficacious antibodies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
